SAN DIEGO, June 8 /PRNewswire-FirstCall/ -- Nanogen, Inc. (Nasdaq: NGEN) today announced that a study published in the European Journal of Heart Failure concluded that for patients with severe congestive heart failure, a significantly higher risk of one-year mortality was associated with elevated levels of N-terminal brain natriuretic peptide (NT-proBNP). NT-proBNP is the protein marker Nanogen is utilizing to develop a point-of-care test to predict congestive heart failure. The published study looked at N-terminal atrial natriuretic peptide (NT-proANP), brain natriuretic peptide (BNP) and NT-proBNP and found all to be significant individual predictors of one-year mortality. The study was co-authored by Dr. Eric Stanton, associate professor of medicine, McMaster University and consultant to Nanogen's subsidiary SynX, and Dr. Peter Kupchak, director of biometry and clinical operations at SynX, and others. The study also showed that the risk of mortality from congestive heart failure can be more accurately ascertained if levels of NT-proBNP are known, even after accounting for other important clinical variables such as the severity of heart failure. Attributes of NT-proBNP, including a longer half-life and higher plasma concentration, can provide benefits as a point-of-care diagnostic in comparison to a test measuring the peptide BNP. These benefits could include accuracy, sensitivity and ease-of-use of the product in a clinical setting. "This is one of the first peer-reviewed studies to validate the utility of Nanogen's NT-proBNP assay as a significant predictor of mortality in a chronic congestive heart failure population, as well as one of the first studies published that compares the three most important markers associated with the disease," said Dr. Stanton. "This study validates the importance of using the single marker NT-proBNP to predict congestive heart failure. By developing a point-of-care diagnostic utilizing this marker, Nanogen takes another step forward in its mission to bring to market diagnostic tools that improve the accessibility and quality of information available to healthcare providers so that they can select the appropriate course of therapy and potentially extend the lives of patients," said Howard C. Birndorf, Nanogen's chairman of the board and CEO. Natriuretic peptides have been validated as sensitive and specific markers of left ventricular dysfunction, and have been associated with heart failure, but there is very little comparative data on these markers in predicting survival in advanced heart failure. The article, titled "A direct comparison of the natriuretic peptides and their relationship to survival in chronic heart failure of a presumed non-ischaemic origin" in Volume 7 Issue 4 (June) of the journal, presents data from a study of evaluated plasma levels of three peptides, BNP, NT-proANP and NT-proBNP, in 153 subjects. The study concluded that the three natriuretic peptides were significant individual predictors of mortality within one year in patients with chronic heart failure. About Nanogen, Inc. Nanogen's advanced diagnostics provide researchers, clinicians, physicians and patients worldwide with improved methods and tests that can predict, diagnose and ultimately help treat disease. Nanogen's products include real-time PCR reagents, the NanoChip(R) Molecular Biology Workstation platform for molecular diagnostic applications and the Nexus Dx(TM) line of point-of-care diagnostic tests for cardiac related health conditions. Nanogen's ten years of pioneering research involving nanotechnology may also have future applications in medical diagnostics, biowarfare and other industries. For additional information please visit Nanogen's website at www.nanogen.com. Forward-Looking Statement This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether patents owned or licensed by Nanogen will be developed into products, whether the patents owned by Nanogen offer any protection against competitors with competing technologies, whether products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in Nanogen's Form 10-K or Form 10-Q most recently filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Nanogen disclaims any intent or obligation to update these forward-looking statements.
SOURCE Nanogen, Inc.